Abstract: AIM: To study whether the glucocorticoid receptor (GR/NR3C1) gene haplotypes influence the steroid therapy outcome in inflammatory bowel disease (IBD). METHODS: We sequenced all coding exons and flanking intronic sequences of the NR3C1 gene in 181 IBD patients, determined the single nucleotide polymorphisms, and predicted the NR3C1 haplotypes. Furthermore, we investigated whether certain NR3C1 haplotypes are significantly associated with steroid therapy outcomes. RESULTS: We detected 13 NR3C1 variants, which led to the formation of 17 different haplotypes with a certainty of > 95% in 173 individuals. The three most commonly occurring haplotypes were included in the association analysis of the influence of haplotype on steroid therapy outcome or IBD activity. None of the NR3C1 haplotypes showed statistically significant association with glucocorticoid therapy success. CONCLUSION: NR3C1 haplotypes are not related to steroid therapy outcome. 
INTRODUCTION
Inflammatory bowel diseases (IBD), Crohn's disease (CD) and ulcerative colitis (UC), are multifactorial disorders, which are characterized by chronic recurrent inflammation of the gastrointestinal tract [1] . The molecular pathogenesis of IBD is not fully elucidated, although an exaggerated mucosal immune response triggered by intestinal bacteria in genetically susceptible individuals appears to play an important role [2] . The combined prevalence of CD and UC is estimated to be 100 to 200 per 100000 individuals in developed countries [3] . IBD shows extensive variation in individual clinical presentation and outcomes, which is likely to be caused by differences in genetic susceptibility, environmental factors, intestinal bacteria and activation of the intestinal immune system [3] . CD is mainly treated with GCs and/or antibiotics, and AZA, 6-MP, or the anti-folate methotrexate (MTX) are often added to maintain the state of remission [4] . GCresistant or -dependent disease courses can be treated with anti-TNF-α antibodies, such as infliximab and adalimumab. GCs are often used in the initial treatment of most cases of moderate to severe active UC or CD. However, 20% of patients develop GC resistance within one year of treatment [5, 6] . Non-response to GCs often leads to the need of a surgical intervention as a result of a poor therapy outcome. For example, it has been reported that 38% and 29% of steroid-resistant CD and UC patients, respectively, required surgery within one year after beginning GC treatment [5] .
Glucocorticoids are potent inhibitors of T cell activation and cytokine secretion, primarily via binding to the cytoplasmically located glucocorticoid receptor (GR) as ligands. Due to ligand binding, homodimers consisting of two activated GRs are formed that translocate into the nucleus. The complex subsequently binds to specific glucocorticoid response elements (GREs) within the regulatory regions of GR target genes [7] . The mechanisms by which GC resistance develops, are not fully understood. Three possible mechanisms have been proposed. First, decreased plasma levels of GCs through overexpression of the drug efflux system P-glycoprotein (MDR1). Second, an altered function of GR or, third, excessive synthesis of pro-inflammatory cytokines induced by activation of pro-inflammatory transcription factors may reduce the affinity of GR to its ligands and lead to the development of GC resistance [4] .
GR is known to be expressed as several polymorphic variants [8] . Several mutations in the NR3C1 gene have been found to modulate individual GC sensitivity in in vitro investigations and in studies with healthy individuals [9, 10] . In the present study we evaluated the association between the NR3C1 gene haplotypes and therapeutic outcome of GC administration in a well-sized cohort of 181 patients with IBD. The aim was to comprehensively determine abundant GR variants by sequencing all protein-coding NR3C1 exons (exons 2 to 9) and the first 50 bp of the neighbouring intronic regions in all individuals. We hypothesized that NR3C1 gene polymorphisms may influence GC sensitivity and thus might serve as predictive markers for treatment success with GCs in IBD patients.
MATERIALS AND METHODS

Patients
One hundred and 85 clinically diagnosed Swiss IBD patients were recruited at the centers participating in the Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS) [11] . All patients gave their informed consent for the inclusion into the study.
An ethical approval was obtained from the Medical Ethical Committees of the University Hospital Lausanne, Switzerland, and all local study sites. All patients had been treated with steroids and past steroid therapy outcome had been recorded. The standard employed criteria for the steroid therapy success or failure are available on the website www.epact.ch. Briefly, an insufficient response upon appropriate treatment in terms of doses and duration was considered a steroid therapy failure.
EDTA-blood samples were stored at the central tissue repository at the Institute of Pathology, University of Bern, Switzerland. The SIBDCS data center at the University Hospital of Lausanne, Switzerland, provided data on past and current disease characteristics and GC therapy outcome. Diagnosis of IBD (CD or UC) was confirmed by the study investigators based on clinical presentation, endoscopic findings and histology.
Sequencing reactions
DNA was extracted from EDTA-blood using the QIAcube robotic workstation and a standard procedure (QIAamp DNA Mini Kit, QIAGEN, Switzerland). The PCR and sequencing primer design was based on the NCBI reference sequence (GenBank accession number NT_029289). Primers for genomic DNA were designed to span all expressed exons (2 to 9) and at least 50 bp of flanking intronic sequences at both 5'-and 3'-ends. The DNA sequences of purified PCR fragments were obtained with an ABI 3730xl sequencing machine. Details of the PCR primers can be found in the Supplemental Table 1 . Optimized PCR conditions, and methods used for subsequent purification and sequencing of the fragments are available upon request.
Haplotype analysis
The PHASE software was used to calculate the haplotypes based on the detected SNPs and mutations in the NR3C1 gene. PHASE predicts in silico haplotypes on the basis of a Bayesian inference algorithm [12, 13] . Haplotype calculations were performed on 181 individuals, from which sequence data of adequate quality were obtained. To allow referral to specific haplotypes, a frequency-based priority criterion was used to name them (e.g. GR_1 for the most often occurring haplotype, Table 3 ).
Calculation of linkage disequilibria
Linkage disequilibria (LD) were calculated using the r 2 statistics. Calculations were performed using the software package Haploview (www.haploview.com).
Statistical analysis
To detect differences in haplotype distribution between groups with different GC therapy outcomes, the Chi-Square test or the Fisher's exact test was used. It was analyzed, whether one or two copies of a specific haplotype were associated with a particular therapy outcome compared to the GR wild-type carriers. If the number of subjects per group was large enough, heterozygous carriers with one wild-type allele and homozygous carriers of one distinct haplotype were analyzed together against homozygous wild-type carriers. The latter calculations were only performed for haplotypes which occurred in a reasonably large (> 40) number. The statistical analysis was performed using the software package SPSS 17 (SPSS Inc., Chicago, IL).
RESULTS
NR3C1 sequence variability
DNA samples from 185 IBD patients (CD or UC) were initially sequenced for the NR3C1 coding exons 2 to 9 and 50 bp of the neighbouring intronic sequences. The sequencing results of 181 individuals were of adequate quality and further used for SNP and haplotype analyses. The sequence data were screened for genetic variations in the NR3C1 gene, using the Basic Local Alignment Search Tool (BLAST; www.ncbi.nih.gov) and the GenBank entry NT_029289 as the reference sequence.
In Table 1 we list the allele frequencies of all detected SNPs within the IBD cohort under study. Thirteen variants were detected, which were -with exception of one mutation (rs6196; P<0.01) -in Hardy-Weinberg equilibrium. All variants were single nucleotide substitutions. Six variants were detected within the intronic regions, whereas seven variants were found in exons (Figure 1) . Three of the seven variants detected within the coding regions of the NR3C1 gene resulted in nonsynonymous amino acid exchanges, while four of them did not lead to changes in the GR amino acid sequence. Eight variants occurred with an allelic frequency of more than one percent (rs56149945, rs6189, rs6190, rs4986593, rs6188, rs258750, rs10482704, rs6196). All non-synonymous amino acid exchanges (R23K, A229T, N363S) were found in the N-terminal half of GR, flanking the N-terminal transactivation domain [14] . The intronic variant found at DNA position 3824968 has not been previously listed in the NCBI SNP database.
Haplotype analysis
The 13 NR3C1 variants described above were included in the haplotype calculations using the computer programme PHASE. All 181 individuals were included in the haplotype prediction analysis (Table 2) . Twenty-five NR3C1 haplotypes were predicted by PHASE to exist in the studied cohort. Furthermore, PHASE determined 17 different distinct haplotypes, which were found to be in best reconstruction for the cohort (Table 3) . Five out of these 17 haplotypes occurred at a frequency higher than 1% ( Figure 1) . PHASE was only able to determine the haplotype structure of 174 individuals out of 181 subjects with a certainty of ≥ 95%. The data of one individual were excluded because of missing demographic data. Thus, the predicted haplotypes of 173 individuals were included in the subsequent association analysis.
The two SNPs E22E/R23K were found to be in complete linkage disequilibrium ( Figure 2 ). This finding is in agreement with previous publications [15] , [16] . Furthermore, a strong but not complete linkage was found between the SNPs rs6188 and rs258750 ( Figure 2 ).
Analysis of NR3C1 haplotypes in relation to steroid therapy outcome
An overview of the demographic data of the 173 subjects included in the association analysis is shown in Table 4 (further patient data on comedications and extraintestinal manifestations are given in Supplemental Tables 2 and 3) , and the haplotype combinations calculated for all patients are shown in Table 5 . As the numbers of homozygous carriers of variant NR3C1 haplotypes were low, the subjects were analyzed as carriers of one or two copies of a distinct variant haplotype, irrespective of whether the other allele was determined to be wild-type or variant in the case of heterozygotes (Table 6 ). Furthermore, haplotypes GR_2 and GR_3 were analyzed by testing the heterozygous allele combinations GR_2+GR_1(wt) together with the homozygous GR_2 subjects and the allele combination GR_3+GR_1(wt) together with homozygous GR_3 carriers against wild-type carriers. For all individuals, prior success of GC therapy was documented, and for patients under GC therapy at the point of study entry the applied dosage was also noted.
No significant associations were observed between haplotype GR_2 and success of GC therapy (Figure 3 ). Upon stratification of the patient cohort according to gender or disease subgroup (UC or CD), no significant association between therapy success or haplotype GR_2 was observed either. Similarly, when stratifying according to the subgroup of heterozygous GR_2+GR_1 and homozygous GR_2, no statistically significant difference in therapy response compared to wild-type carriers could be observed.
No significant associations were observed between either haplotype GR_3 (Figure 4) or GR_4 (Table 6 ) and GC therapy outcome, or between individual SNPs and therapy success ( Figure 5 ). Similarly, we observed no significant associations between the severity of disease (active or inactive state of UC or CD) or currently taken GC dose levels and NR3C1 haplotypes (data not shown).
DISCUSSION
Glucocorticoid receptor (GR) plays an important role in many physiological and pathological processes and is the main target of glucocorticoids, widely used as therapeutic agents to treat a variety of autoimmune diseases [8, 17] . Two GR isoforms, GR and GR, generated by alternative mRNA splicing exist [18] . Only GR can be activated by glucocorticoid ligands, while GR does not bind glucocorticoids and may in fact act as an inhibitor of glucocorticoid action [19] . Genetic variation in the NR3C1 gene has been shown to affect both disease pathophysiology and response to glucocorticoid therapy [15, 20, 21, 22] , suggesting that SNPs might play a role in GR function and associated steroid therapy outcome also in IBD patients. GR is known to regulate the intestinal bile acid uptake transporter ASBT [23, 24] , the expression of which is altered in IBD patients [25] . While it has been reported that GR mRNA expression levels are not predictors of steroid response in IBD [26] and that the GR polymorphisms R23K and N363S are not associated with CD in a pediatric Caucasian population [27] , no studies on the role of NR3C1 gene variants in steroid therapy success were previously available. The aim of the current study was to analyze sequence variation and haplotype structures in the coding parts of the NR3C1 gene in a cohort of 181 Swiss IBD patients. We investigated, whether NR3C1 genetic variants or haplotypes may influence steroid therapy outcome in IBD patients.
We identified 13 variants in this study, of which 12 had already been previously submitted to the NCBI SNP database. We calculated the corresponding haplotypes in the IBD patient cohort and studied the association of the most prevalent SNP combinations with steroid therapy outcome, disease activity, and age of disease onset. Several NR3C1 SNPs have been previously associated with altered disease susceptibility or risk of disease progression in other autoimmune diseases, such as Guillain Barré-Syndrome or multiple sclerosis [15, 20] . Most of these studies only analyzed the impact of a small number of pre-defined SNPs, such as the BclI polymorphism or the E22E/R23K polymorphisms [15, 20, 21] . Few reports have been published on the potential influence of NR3C1 SNPs on sensitivity to endogenous or exogenously given GCs [17, 28] , and only one significant association between the polymorphism E22E/R23K and sensitivity to exogenously administered GCs in elderly Dutch people has been reported [22] . So far no large cohort studies have been reported, in which the influence of NR3C1 SNPs on GC therapy outcome in IBD patients has been investigated. Here, we describe five NR3C1 haplotypes occurring at a frequency >1% and analyze the potential association of the three most common haplotypes GR_2, GR_3 and GR_4 with GC therapy outcome in IBD patients. While a large number of NR3C1 variants are already registered in the NCBI SNP database, we observed only eight variants that occurred at a frequency >1%, and these were responsible for the composition of a relatively small group of commonly occuring haplotypes. The overall risk for a certain UC and/or CD activity state or for a different steroid therapy outcome was not altered in GR_2, GR_3 or GR_4 carriers, in comparison with the wild-type carriers. Furthermore, no significant associations were observed between individual SNPs and GC therapy success. In the case of certain SNPs/haplotypes (e.g. GR_4, E22E/R23K), a larger cohort would have been preferable in order to obtain more reliable results, as these variants occurred quite rarely in our patient group. Similarly to our observations, Dekker et al. could not detect any associations between distinct haplotypes and SNPs in a Guillan Barré-Syndrome cohort treated with methylprednisolone, although the authors noted that their study group was too small to obtain statistically reliable results [20] . It remains to be seen whether the rare GR variants present in our study cohort will show significant associations in larger cohorts of IBD patients.
In conclusion, we have performed a comprehensive study analyzing the role of genetic variants in the NR3C1 gene in glucocorticoid sensitivity in a Swiss cohort of IBD patients. We show that NR3C1 haplotypes are not a general modulating factor in glucocorticoid therapy outcome. 
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Background
Crohn's disease and ulcerative colitis are two distinct types of inflammatory bowel disease (IBD), which is an increasingly prevalent disease condition worldwide. Wide variation is observed in clinical manifestation and therapy responses in IBD, partly due to individual genetic variation.
Research frontiers
Glucocorticoid therapy is commonly used in treatment of IBD, however the response to therapy varies between individuals. We hypothesized that genetic variation in the NR3C1 gene encoding the glucocorticoid receptor (GR) may affect the response to glucocorticoids in IBD patients.
Innovations and breakthroughs
In our comprehensive genetic analysis, all coding exons and exon-intron junctions of the NR3C1 gene were sequenced in 181 IBD patients, who had been treated with glucocorticoids and whose past responses to this treatment had been recorded. To our knowledge, this is the first published study on the effects of genetic variation in GR on glucocorticoid therapy in IBD patients, in a modestly sized study cohort.
Applications
If significant associations between genetic GR variants and glucocorticoid therapy outcome had been observed, this could have allowed more considered design of the individual therapy options upon prior genotyping of the patients.
Terminology
The transcription factor of the steroid receptor family, GR, is proposed to be a major mediator of anti-inflammatory pathways elicited by therapeutically administered glucocorticoids.
Peer review
In this study, no associations were found between the GR polymorphisms and effectiveness of steroid therapy. This may suggest that the efficacy of glucocorticoid therapy in IBD may be determined by other factors.
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Figure Legends Odds ratios and confidence intervals for the number of GR_2 carriers versus wildtype carriers in the responder group compared with non-responders to GC therapy.
No significant associations were found. Statistical analysis was performed with
Fisher's exact test. OR, odds ratio; CI, confidence interval.
FIGURE 4. Haplotype GR_3 and steroid therapy outcome.
Odds ratios and confidence intervals for the number of GR_3 carriers versus wildtype carriers in the responder group of responders compared with non-responders to GC therapy. No significant associations were found. Statistical analysis was performed using Fisher's exact test. OR, odds ratio; CI, confidence interval. Odds ratios and confidence intervals for carriers of six SNPs against wild-type carriers in the group of GC responders compared with GC non-responders. No significant associations were found. Statistical analysis was performed using chisquare or Fisher's exact test. OR, odds ratio; CI, confidence interval. Table 3 
